title: Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
abstract: Multiple sclerosis (MS) is mediated primarily by autoreactive T cells. However, evidence suggesting the involvement of humoral immunity in brain diseases has increased interest in the role of B cells and their products during MS pathogenesis. The major survival factor for B cells, BAFF has been shown to play a role in several autoimmune conditions. Elevated BAFF levels have been reported in MS animal model and during MS relapse in patients. Moreover, disease-modifying treatments (DMT) reportedly influence blood BAFF levels in MS patients, but the significance of these changes remains unclear. The present study addresses how blood BAFF levels are associated with the clinical course of relapsing-remitting MS and the effectiveness of DMT and short-term steroid treatment. During a prospective longitudinal follow-up of 2.3 years, BAFF was measured in the blood of 170 MS patients in the stable phase and within 186 relapses. BAFF levels were significantly higher in MS patients compared to healthy controls. However, stable MS patients without relapses exhibited significantly higher BAFF levels than relapsing patients. Treatment with interferon-β and immunosuppressants raised BAFF blood levels. Interestingly, a similar effect was not seen in patients treated with glatiramer acetate. Short-term treatment with high doses of intravenous methylprednisolone did not significantly alter plasma BAFF levels in 65% of relapsing-remitting MS patients. BAFF were correlated weakly but significantly with monocyte and basophil counts, but not with other blood cell types (neutrophils, lymphocytes, or eosinophils) or inflammatory biomarkers. To our knowledge, this is the first report demonstrating that higher blood BAFF levels may reflect a more stable and effective MS treatment outcome. These results challenge hypotheses suggesting that elevated blood BAFF levels are associated with more severe disease presentation and could explain the recent failure of pharmaceutical trials targeting BAFF with soluble receptor for MS treatment.
authors.affiliation: West-Tallinn Central Hospital MS Centre, Tallinn, Estonia.
authors.forename: Karin
authors.initials: K
authors.lastname: Kannel
authors.affiliation: Department of Immunology, Institute of Biomedicine and Translational Medicine, Tartu University, Tartu, Estonia.
authors.forename: Kristi
authors.initials: K
authors.lastname: Alnek
authors.affiliation: West-Tallinn Central Hospital MS Centre, Tallinn, Estonia.|Institute of Psychology, Tallinn University, Tallinn, Estonia.
authors.forename: Liina
authors.initials: L
authors.lastname: Vahter
authors.affiliation: West-Tallinn Central Hospital MS Centre, Tallinn, Estonia.|Institute of Clinical Medicine, Tallinn University of Technology, Tallinn, Estonia.
authors.forename: Katrin
authors.initials: K
authors.lastname: Gross-Paju
authors.affiliation: Department of Immunology, Institute of Biomedicine and Translational Medicine, Tartu University, Tartu, Estonia.
authors.forename: Raivo
authors.initials: R
authors.lastname: Uibo
authors.affiliation: Department of Immunology, Institute of Biomedicine and Translational Medicine, Tartu University, Tartu, Estonia.
authors.forename: Kalle V
authors.initials: KV
authors.lastname: Kisand
mesh_terms: D061605:Administration, Intravenous; D000328:Adult; D053264:B-Cell Activating Factor / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008954:Models, Biological; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood* / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D053264:B-Cell Activating Factor; D015415:Biomarkers; D018836:Inflammation Mediators; C505719:TNFSF13B protein, human; D008775:Methylprednisolone